{
    "organizations": [],
    "uuid": "6e64e355d35e0487213bb6e879bdbb4041da3e1d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-mersana-therapeutics-q4-loss-per-s/brief-mersana-therapeutics-q4-loss-per-share-0-61-idUSASC09TXY",
    "ord_in_thread": 0,
    "title": "BRIEF-Mersana Therapeutics Q4 Loss Per Share $0.61",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 45 AM / Updated 9 minutes ago BRIEF-Mersana Therapeutics Q4 Loss Per Share $0.61 Reuters Staff \nMarch 28 (Reuters) - Mersana Therapeutics Inc: \n* MERSANA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES * Q4 LOSS PER SHARE $0.61 \n* Q4 EARNINGS PER SHARE VIEW $-0.50 â€” THOMSON REUTERS I/B/E/S \n* ENROLLMENT ON TRACK FOR PHASE 1 TRIAL OF XMT-1522 PATIENTS WITH ADVANCED TUMORS EXPRESSING HER2 \n* COLLABORATION REVENUE FOR Q4 2017 WAS ABOUT $3.3 MILLION VERSUS $12.0 MILLION FOR SAME PERIOD IN 2016 \n* CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF DECEMBER 31, 2017 WERE $125.2 MILLION \n* MERSANA THERAPEUTICS - EXPECTS CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL ENABLE CO TO FUND OPERATING PLAN THROUGH AT LEAST MID-2019 Source text for Eikon: Further company coverage:",
    "published": "2018-03-28T14:43:00.000+03:00",
    "crawled": "2018-03-28T15:06:25.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "q4",
        "loss",
        "per",
        "share",
        "reuters",
        "staff",
        "march",
        "reuters",
        "mersana",
        "therapeutic",
        "inc",
        "mersana",
        "therapeutic",
        "announces",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "provides",
        "business",
        "update",
        "q4",
        "loss",
        "per",
        "share",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "enrollment",
        "track",
        "phase",
        "trial",
        "patient",
        "advanced",
        "tumor",
        "expressing",
        "her2",
        "collaboration",
        "revenue",
        "q4",
        "million",
        "versus",
        "million",
        "period",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "december",
        "million",
        "mersana",
        "therapeutic",
        "expects",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "enable",
        "co",
        "fund",
        "operating",
        "plan",
        "least",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}